https://www.novumpr.nl/2016/06/06/exelixis-and-its-partner-ipsen-announce-phase-3-trial-results-of-cabometyx-cabozantinib-tablets-demonstrating-significant-overall-survival-benefit-for-previously-treated-patients-with-advan/?utm_source=rss&utm_medium=rss&utm_campaign=exelixis-and-its-partner-ipsen-announce-phase-3-trial-results-of-cabometyx-cabozantinib-tablets-demonstrating-significant-overall-survival-benefit-for-previously-treated-patients-with-advan NovumPR press releases Mon, 06 Jun 2016 10:20:32 +0000 hourly 1 https://wordpress.org/?v=6.8.3